Raphael Pharmaceutical (RAPH) Debt to Equity (2020 - 2025)

Raphael Pharmaceutical has disclosed Debt to Equity across 5 years of filings, most recently posting -$0.02 for Q4 2025.

• Debt to Equity for Q4 2025 came in at -$0.02, up 57.06% year-over-year; the trailing twelve-month figure through Dec 2025 was -$0.02 (up 57.06% YoY), and the FY2025 annual result was -$0.02, up 57.06% from the prior year.
• Debt to Equity came in at -$0.02 for Q4 2025 at Raphael Pharmaceutical, up from -$0.03 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $0.17 in Q4 2021 to a low of -$0.06 in Q1 2025.
• The 4-year median for Debt to Equity is -$0.02 (2025), against an average of $0.01.
• Across the five-year window, Debt to Equity jumped 182.12% in 2021 and tumbled 83.53% in 2022, its largest moves.
• Raphael Pharmaceutical's Debt to Equity stood at $0.17 in 2021, then sank by 83.53% to $0.03 in 2022, then sank by 295.24% to -$0.06 in 2024, then jumped by 57.06% to -$0.02 in 2025.
• The last three Debt to Equity figures came in at -$0.02 (Q4 2025), -$0.03 (Q3 2025), and -$0.04 (Q2 2025), per Business Quant data.